The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.

Letter to the editor

Editor, – I would like to inform the readers of Australian Prescriber about the ongoing technical appraisal of the newer hypnotics by the UK National Institute for Clinical Excellence. The final statement should appear in the very near future.1 It will offer information which might complement the recent excellent article by Professor Tiller (Aust Prescr 2003;26:78-81), particularly in clarifying pharmacoeconomic issues.

Dragan Milovanovic
Department of Basic and Clinical Pharmacology
Medical Faculty and University Hospital
Kragujevac, Serbia
Serbia and Montenegro


  1. National Institute for Clinical Excellence. Technology appraisals in progress: Final Scope - Zaleplon, zolpidem and zopiclone for the management of insomnia.